Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Long-Term Deferred Tax (2023 - 2024)

Historic Long-Term Deferred Tax for ARS Pharmaceuticals (SPRY) over the last 2 years, with Q4 2024 value amounting to $36.9 million.

  • ARS Pharmaceuticals' Long-Term Deferred Tax rose 2692.12% to $36.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $36.9 million, marking a year-over-year increase of 2692.12%. This contributed to the annual value of $36.9 million for FY2024, which is 2692.12% up from last year.
  • ARS Pharmaceuticals' Long-Term Deferred Tax amounted to $36.9 million in Q4 2024, which was up 2692.12% from $29.0 million recorded in Q4 2023.
  • In the past 5 years, ARS Pharmaceuticals' Long-Term Deferred Tax registered a high of $36.9 million during Q4 2024, and its lowest value of $29.0 million during Q4 2023.